Deliver Biosciences

Executive Summary

Deliver Biosciences, a UK-based biotechnology company founded in 2021, is pioneering a nanoparticle-based delivery platform for in vivo genetic engineering. The company aims to develop scalable, affordable, and potent cell and gene therapies by directly reprogramming cells within the patient's body. Its initial focus is on generating CAR-T cells for cancer immunotherapy, with long-term applications in autoimmune, neurodegenerative, and cardiovascular diseases. The platform has the potential to overcome key limitations of ex vivo cell therapies, including high cost and manufacturing complexity. Despite being early-stage with undisclosed funding and no public milestones, the company's innovative approach addresses a significant unmet need in the cell therapy space. The team's location in Cambridge, a leading biotech hub, and the growing interest in in vivo reprogramming technologies position Deliver Biosciences as a promising player in the RNA therapeutics and drug delivery landscape. However, the company faces substantial technical and regulatory hurdles typical of early-stage biotechs, and its success hinges on demonstrating robust preclinical efficacy and safety.

Upcoming Catalysts (preview)

• Q4 2026In Vivo Proof-of-Concept Data for CAR-T Platform40% success
• Q1 2027Series A Financing Round50% success
• Q3 2027First IND Filing for Lead Candidate20% success